Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
63°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by SAB Biotherapeutics, Inc.
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
May 06, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Provides SAB-142 Trial Update
April 16, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics to Present at INNODIA Annual Meeting
April 08, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
April 04, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
March 25, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
February 23, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 08, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Announces Executive Leadership Change
February 02, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
January 23, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
January 02, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
November 29, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
November 20, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes
November 14, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates
November 14, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference
November 09, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer
October 24, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
October 19, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors
October 05, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
October 02, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results
August 21, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023
June 21, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention
May 30, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations
May 19, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results
May 16, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies
May 12, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ Platform
May 09, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG Conference
May 04, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics to Present at Sidoti Virtual Investor Conference, May 10-11
May 03, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications
April 26, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy
April 18, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.